A LEUCINE TRIPLET REPEAT SEQUENCE (LXX)(4) IN P6(GAG) IS IMPORTANT FOR VPR INCORPORATION INTO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PARTICLES

被引:119
作者
LU, YL
BENNETT, RP
WILLS, JW
GORELICK, R
RATNER, L
机构
[1] WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110
[2] WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110
[3] WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110
[4] PENN STATE UNIV,COLL MED,DEPT IMMUNOL & MICROBIOL,HERSHEY,PA 17033
[5] NCI,FREDERICK CANC RES & DEV CTR,SAIC,AIDS VACCINE PROGRAM,FREDERICK,MD 21701
关键词
D O I
10.1128/JVI.69.11.6873-6879.1995
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Incorporation of Vpr into human immunodeficiency virus type 1 (HIV-1) virions is mediated by the Gag protein, independently of other viral components. We have coexpressed Vpr and Gag constructs in a vaccinia virus expression system in order to map the region of Gag involved in Vpr packaging. Deletion of the carboxyl-terminal p6 region of Gag impaired the ability of Gag to package Vpr. To confirm the role of p6 in Vpr packaging, Rous sarcoma virus (RSV)-HIV chimeras containing HIV-1 p6 were constructed. Although RSV Gag does not package Vpr into virus particles, a chimera containing HIV-1 p6 is sufficient for Vpr incorporation. To map the region of p6 involved in Vpr packaging, a series of p6 point mutations and deletion mutations was analyzed. Mutations in the N-terminal p6 proline-rich domain, for which preliminary evidence shows a marked decrease in virion incorporated RNA, did not affect Vpr incorporation. Deletion of residues 1 to 31 of HIV-1 p6 did not affect Vpr packaging, but residues 35 to 47, including an (LXX)(4) domain, were required for Vpr incorporation into virus particles.
引用
收藏
页码:6873 / 6879
页数:7
相关论文
共 49 条
[1]   DISTINCT EFFECTS IN PRIMARY MACROPHAGES AND LYMPHOCYTES OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ACCESSORY GENES VPR, VPU, AND NEF - MUTATIONAL ANALYSIS OF A PRIMARY HIV-1 ISOLATE [J].
BALLIET, JW ;
KOLSON, DL ;
EIGER, G ;
KIM, FM ;
MCGANN, KA ;
SRINIVASAN, A ;
COLLMAN, R .
VIROLOGY, 1994, 200 (02) :623-631
[2]  
BALOTTA C, 1993, J VIROL, V64, P4409
[3]   FUNCTIONAL CHIMERAS OF THE ROUS-SARCOMA VIRUS AND HUMAN-IMMUNODEFICIENCY-VIRUS GAG PROTEINS [J].
BENNETT, RP ;
NELLE, TD ;
WILLS, JW .
JOURNAL OF VIROLOGY, 1993, 67 (11) :6487-6498
[4]   GENETIC-EVIDENCE THAT THE TAT PROTEINS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND TYPE-2 CAN MULTIMERIZE IN THE EUKARYOTIC CELL-NUCLEUS [J].
BOGERD, HP ;
FRIDELL, RA ;
BLAIR, WS ;
CULLEN, BR .
JOURNAL OF VIROLOGY, 1993, 67 (08) :5030-5034
[5]  
COHEN AA, 1990, J ACQ IMMUN DEF SYND, V3, P11
[6]   HUMAN-IMMUNODEFICIENCY-VIRUS VPR PRODUCT IS A VIRION-ASSOCIATED REGULATORY PROTEIN [J].
COHEN, EA ;
DEHNI, G ;
SODROSKI, JG ;
HASELTINE, WA .
JOURNAL OF VIROLOGY, 1990, 64 (06) :3097-3099
[7]   AN INFECTIOUS MOLECULAR CLONE OF AN UNUSUAL MACROPHAGE-TROPIC AND HIGHLY CYTOPATHIC STRAIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
COLLMAN, R ;
BALLIET, JW ;
GREGORY, SA ;
FRIEDMAN, H ;
KOLSON, DL ;
NATHANSON, N ;
SRINIVASAN, A .
JOURNAL OF VIROLOGY, 1992, 66 (12) :7517-7521
[8]   VPR IS REQUIRED FOR EFFICIENT REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN MONONUCLEAR PHAGOCYTES [J].
CONNOR, RI ;
CHEN, BK ;
CHOE, S ;
LANDAU, NR .
VIROLOGY, 1995, 206 (02) :935-944
[9]   VIRAL PROTEIN-R OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 AND TYPE-2 IS DISPENSABLE FOR REPLICATION AND CYTOPATHOGENICITY IN LYMPHOID-CELLS [J].
DEDERA, D ;
HU, W ;
VANDERHEYDEN, N ;
RATNER, L .
JOURNAL OF VIROLOGY, 1989, 63 (07) :3205-3208
[10]   EUKARYOTIC TRANSIENT-EXPRESSION SYSTEM BASED ON RECOMBINANT VACCINIA VIRUS THAT SYNTHESIZES BACTERIOPHAGE-T7 RNA-POLYMERASE [J].
FUERST, TR ;
NILES, EG ;
STUDIER, FW ;
MOSS, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (21) :8122-8126